Clinical trials
Advanced Solid Tumor Cancer clinical trials
Below are recruiting advanced solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,359 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
San Francisco, CaliforniaAges 18 years+ - NCT06262919Recruiting
Monitoring safety of Tafinlar/Mekinist for BRAF-positive tumors
This study tracks the safety of the combination therapy Tafinlar and Mekinist in people with advanced or returning solid tumors that have a BRAF mutation, except for colorectal cancer. It aims to make sure the treatment is safe in the real world.
Nagakute, Aichi-kenAges 6–99 - NCT06410092RecruitingPhase 1
Safety study of FTL001 for advanced solid tumors
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18–75 - NCT07600749RecruitingPhase 1
MK-4884 study for advanced solid tumors
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
San Antonio, TexasAges 18 years+ - NCT07708935Recruiting
Study of young patients with solid tumors in China
This study looks at young people (40 or younger at diagnosis) with solid tumors in China. It aims to collect real-world information about their treatments and outcomes to find patterns that could help improve care.
ShanghaiAges 18–80 - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Scottsdale, ArizonaAges 12–85 - NCT06013111RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new treatment called Anti-CEA-CAR-T cells, which are specially modified immune cells that target a protein called CEA found on certain cancer cells. It is for people with advanced solid tumors, especially digestive system cancers, that have not responded to other treatments.
Shenyang, LiaoningAges 18–70 - NCT06504732RecruitingPhase 2/Phase 3
IAH0968 plus CAPEOX for HER2-positive gastric cancer
This trial tests a new drug (IAH0968) combined with chemotherapy (CAPEOX) for people with HER2-positive stomach or gastroesophageal junction cancer that has not been treated before or has spread.
Harbin, HeilongjiangAges 18–75 - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT07646106RecruitingPhase 1
Testing THE-0504 in Advanced Solid Tumors
This Phase 1 trial tests a new drug called THE-0504 in patients with advanced solid tumors (like lung, colon, pancreas, stomach, or breast cancer) that have not responded to standard treatments. The study aims to find the right dose and understand how well and safely the drug works.
Rome, LazioAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06454383RecruitingPhase 1
Gemcitabine and leflunomide for advanced pancreatic cancer
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Duarte, CaliforniaAges 18 years+ - NCT07394374RecruitingPhase 1/Phase 2
CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
BeijingAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06612632RecruitingPhase 1/Phase 2
Retrying Immunotherapy for Solid Tumors After First Trial
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
BeijingAges 18 years+ - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Iowa City, IowaAges 18–100 - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT06515314RecruitingPhase 1
TCR-T cell therapy for AFP-positive liver and other cancers
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor cancer?
- Yes. Clin2 currently lists 1,359 recruiting advanced solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.